{"ticker": {"uuid": "04bcbcf5-f8aa-4784-84d7-6354d56388b7", "symbol": "OSE", "name": "OSE Immunotherapeutics SA", "exchange": "PAR", "country": "FR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPeG5MUkRyX283Z0xnS1BPMS0yRW5wa2h3dm1xNkdZbDZzU2ZyR3dLRHN4bExaNVg1el9vSGI2VzRYXzlBdE1GeTNqVGFFdm1zcmN1aHl0YXhtVUpCeEwxRm5Ka2QtYm5CcmlUbGVhZ0VheVU1a2VXWmpwLTZFS0R4UFA0T2lLOGdVekpYc3R5OGZxVV9maVlBcnlpTlY5bkp0dDM4Z0NsTlVNZFp1V2RaaWhMZw?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OSE Immunotherapeutics: Net Loss of \u20ac37.7M in 2025, Cash Available Until Early Q4 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPYUZVaFpJeDRnbnpfLTFNUVVTR2hyNUtSdWcyZkNEaFZnZFdFdy1ZUHRYaUUwT25ZWG9rdWd4OUQyS3J3c3RMZ2ZpMldlMFVFSlZhTUtSWE1vWkhIMWM1U0dkODliQWM1MEY4T1ZmSTZ1SHVuZHN3bUNSaXFGaHN2T2t6YUF0Tzh6QWdvVjMyREdsMFNjZmhfcjUySzJ6LTJRcWc2NFpaUVJDMjkzTFpjSUdLRHNrMWU3Nmc0YnJCTnZISkRlcUtSZkdJTlZrWjZiVXhERE1RaEZ5MWhaN1E?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OSE Immunotherapeutics: FDA Grants Orphan Drug Designation to Anti-Rejection Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNWDlyRzg4RW96SE9XQklVSy1JUjRGMnZkcWt3aHBoeHpFODZvRERJYi11c01Lb2Z2cVltTFhVUzRRMUF5YTB0Z3VfYUpqMGRobzBHd0wwRDhTTTFCS29mQng3WXU3MEJwcXhzYzcxZlZNZ2R4VkxfWnRMUXk3dmhELW11WnprX21HY0RJX0d4Z0tpS0hDUXdicEdnZXNIRzdiYnNNajJpd1F5UUlDTXNxMVhiYzVhRW9wRHIyRTMwQmlFMGx1bFZFaDlwYWVlOUVuN09TR1BDN05iOWJi?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQWW5aMHctWGhYNjNUZlVURHBUN0hhM2RINjFtaGFjbzlsOGg1MW9FUTFBTTZETW1fWHp6YkNfVV80cVUxRmR2bTFDTjMwRURzVnZJWWFqSUt5ajhzZWlKclJjWFFCaGFyYVZvTi15MUVnci1NSjZSbDI5SzNhU3lQMDh4VU5KaEpKQ243YVhPMzNIS1lTazF4TVo5ZVM0OHFMNEtNa1JPVTNRR1NrTWZUU2hGb2dORDhRLVYwaVlFdUdpTjFaakdLaXd2ZHlJODlhbmR2dmdINkZrUVpuY3ZCbDhXcm5QSHVONERNTndpbWwza3fSAfgBQVVfeXFMTjd1YTZlNDhiNEIxV1I4Nk1uY2RnVXN6SF9xdjFNMTFwcmFDcWJSNlpTY0pCeE44NjNRYi00eWZJem5WaDI2a0U4ZGg1Z2dfTWJqdVM3YkQ3RHJ6LUhjWG1PSHM1RTFEbjNMRnFQazdLaFdpWlhYeTRid05NUy1vbHdLbnZ6QndwZkdqMXM3WlEyd0hzT1ZTSDdZa21PNXdVMWRaTk5uZWFpTHBqYWxkYmIzbnZyY0JSSjNGRjRzem9HemlwZWw5LXMwMVF6dGZBQ2Z2NVJRN0JZX2lFQmRxX2tVbW42UjdWNDFPVHk5UENXLS1xbzB4OU0?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OSE Immunotherapeutics Unveils 2026\u20132028 Strategic Plan With Four Opportunities for Value Creation", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxObEpzYlJLdzZ4andsSmhlTG9LX3Q1X2FxNmw1N3RxUTV0TV9DeTYzRV9nUWZheEJTYVUzSWdlVlVzWDdYbVZfZDh5NENJMjNBSGZJTjZIelVvZ2t5Szl6M1AwakIzWTg2OVE3RDl4R1VOY1RhLUFjLVpXSjB0X1NYOVluaktiaUNnelpLZ2VJOA?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPeG5MUkRyX283Z0xnS1BPMS0yRW5wa2h3dm1xNkdZbDZzU2ZyR3dLRHN4bExaNVg1el9vSGI2VzRYXzlBdE1GeTNqVGFFdm1zcmN1aHl0YXhtVUpCeEwxRm5Ka2QtYm5CcmlUbGVhZ0VheVU1a2VXWmpwLTZFS0R4UFA0T2lLOGdVekpYc3R5OGZxVV9maVlBcnlpTlY5bkp0dDM4Z0NsTlVNZFp1V2RaaWhMZw?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OSE Immunotherapeutics: Net Loss of \u20ac37.7M in 2025, Cash Available Until Early Q4 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPYUZVaFpJeDRnbnpfLTFNUVVTR2hyNUtSdWcyZkNEaFZnZFdFdy1ZUHRYaUUwT25ZWG9rdWd4OUQyS3J3c3RMZ2ZpMldlMFVFSlZhTUtSWE1vWkhIMWM1U0dkODliQWM1MEY4T1ZmSTZ1SHVuZHN3bUNSaXFGaHN2T2t6YUF0Tzh6QWdvVjMyREdsMFNjZmhfcjUySzJ6LTJRcWc2NFpaUVJDMjkzTFpjSUdLRHNrMWU3Nmc0YnJCTnZISkRlcUtSZkdJTlZrWjZiVXhERE1RaEZ5MWhaN1E?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OSE Immunotherapeutics: FDA Grants Orphan Drug Designation to Anti-Rejection Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNWDlyRzg4RW96SE9XQklVSy1JUjRGMnZkcWt3aHBoeHpFODZvRERJYi11c01Lb2Z2cVltTFhVUzRRMUF5YTB0Z3VfYUpqMGRobzBHd0wwRDhTTTFCS29mQng3WXU3MEJwcXhzYzcxZlZNZ2R4VkxfWnRMUXk3dmhELW11WnprX21HY0RJX0d4Z0tpS0hDUXdicEdnZXNIRzdiYnNNajJpd1F5UUlDTXNxMVhiYzVhRW9wRHIyRTMwQmlFMGx1bFZFaDlwYWVlOUVuN09TR1BDN05iOWJi?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OSE Immunotherapeutics Unveils 2026\u20132028 Strategic Plan With Four Opportunities for Value Creation", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxObEpzYlJLdzZ4andsSmhlTG9LX3Q1X2FxNmw1N3RxUTV0TV9DeTYzRV9nUWZheEJTYVUzSWdlVlVzWDdYbVZfZDh5NENJMjNBSGZJTjZIelVvZ2t5Szl6M1AwakIzWTg2OVE3RDl4R1VOY1RhLUFjLVpXSjB0X1NYOVluaktiaUNnelpLZ2VJOA?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 76, "total_relevant": 5, "sentiment_summary": {"positive": 0, "negative": 1, "neutral": 4, "score": 47, "total": 5, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 68, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 0, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 3.32, "latest_week": "2026-07-10", "one_week_move": -11.0, "four_week_move": -14.6, "twelve_week_move": -0.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.150769, "market_dynamics_buy_signal": false, "relative_strength": -33.884215, "fair_value_gap": -40.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.7812, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-11.0% over one week, -14.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 2}, {"label": "Id\u00e9al Investisseur", "count": 2}, {"label": "simplywall.st", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 5}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "68/100 classification confidence."}, {"label": "Company focus", "value": "5", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-11.0% over one week, -14.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing"}], "updated_at": "2026-07-17T06:32:23.070556+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}